首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Multidimensional approaches in dealing with prostate cancer
Authors:Ali Safdar  Ali Sher
Institution:Molecular Genetics Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi-110067, India.
Abstract:Prostate cancer is one of the most prevalent malignancies worldwide affecting the human male population. Different case-control, cohort or twin studies and segregation analyses point towards the presence of prostate cancer-susceptibility genes in the population. The studies have shown linkage of prostate susceptibility genes to multiple loci on chromosome 1 and single locus each on chromosomes 4, 8, 16, 17, 19, 20 and X chromosome. However, differences right from the mode of inheritance (autosomal dominant or X-linked recessive) to the target genes exist. There have been reports supporting no or weak linkage to these loci as well. Also, region (environmental factors), age and dietary habits have implications in different aspects of the disease. The important targets for treating prostate cancer are androgens and estrogen (synthesized from androgens by the action of enzyme aromatase) owing to their involvement in development and progression of prostate cancer. Further, prostate gland needs androgens (male hormones) for its normal maintenance and functioning. Besides, radiation therapy and surgical methods have also been used. The emerging areas include identifying and preparing successful vaccines from candidate peptides and gene therapy in several forms. This review deals with the paradox of linkage analyses and the various approaches in practice for treatment and management of prostate cancer.
Keywords:AR  androgen receptor  ARE  androgen response element  CaP  carcinoma of prostate  CBP  Creb-Binding Protein  CPA  cyproterone acetate  CT  computed tomography  EDT  estrogen deprivation therapy  ER  estrogen receptor  GM-CSF  granulocyte macrophage colony-stimulating factor  HPCX  hereditary prostate cancer  X-linked  HPC  hereditary prostate cancer  IMRT  intensity-modulated radiation therapy  LOD  logarithm of the odds (to the base 10)  MAB  maximal androgen blockade  MRI  magnetic resonance imaging  MRS  magnetic resonance spectroscopy  MRSI  magnetic resonance spectroscopy imaging  PAP  prostatic-acid phosphatase  PCa  prostate cancer  PCAP  predisposing for prostate cancer  PIN  prostate intraepithelial neoplasia  PSA  prostate-specific antigen  PSMA  prostate-specific membrane antigen  SRC1  steroid coactivator 1  TRAMP  transgenic adenocarcinoma of the prostate  
本文献已被 ScienceDirect PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号